NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
Clinical Trials
4 trialsNCT06615479 2026-03-17
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting